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Reactive oxygen species 
A B S T R A C T   
Mitochondrial energy production and function rely on optimal concentrations of the essential redox-active lipid, 
coenzyme Q (CoQ). CoQ deficiency results in mitochondrial dysfunction associated with increased mitochondrial 
oxidative stress and a range of pathologies. What drives CoQ deficiency in many of these pathologies is unknown, 
just as there currently is no effective therapeutic strategy to overcome CoQ deficiency in humans. To date, large- 
scale studies aimed at systematically interrogating endogenous systems that control CoQ biosynthesis and their 
potential utility to treat disease have not been carried out. Therefore, we developed a quantitative high- 
throughput method to determine CoQ concentrations in yeast cells. Applying this method to the Yeast Dele-
tion Collection as a genome-wide screen, 30 genes not known previously to regulate cellular concentrations of 
CoQ were discovered. In combination with untargeted lipidomics and metabolomics, phosphatidylethanolamine 
N-methyltransferase (PEMT) deficiency was confirmed as a positive regulator of CoQ synthesis, the first iden-
tified to date. Mechanistically, PEMT deficiency alters mitochondrial concentrations of one-carbon metabolites, 
characterized by an increase in the S-adenosylmethionine to S-adenosylhomocysteine (SAM-to-SAH) ratio that 
reflects mitochondrial methylation capacity, drives CoQ synthesis, and is associated with a decrease in mito-
chondrial oxidative stress. The newly described regulatory pathway appears evolutionary conserved, as ablation 
of PEMT using antisense oligonucleotides increases mitochondrial CoQ in mouse-derived adipocytes that 
translates to improved glucose utilization by these cells, and protection of mice from high-fat diet-induced insulin 
resistance. Our studies reveal a previously unrecognized relationship between two spatially distinct lipid path-
ways with potential implications for the treatment of CoQ deficiencies, mitochondrial oxidative stress/ 
dysfunction, and associated diseases.   
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1. Introduction 
Mitochondrial dysfunction is increasingly recognized as a central 
mediator of many common disorders, including cardiovascular and 
metabolic diseases via the key role mitochondria play in cellular energy 
homeostasis and oxidant production. One of the central determinants of 
mitochondrial function is ubiquinone (or coenzyme Q, CoQ), an essen-
tial, evolutionarily conserved, redox active lipid in aerobic organisms. 
CoQ is best known for its function in mitochondrial ATP production, 
antioxidant protection and cell survival. More recently, the role of 
mitochondrial CoQ has expanded to the regulation of ferroptosis [1,2] 
nitric oxide synthase [3] and the homeostasis of brown adipose tissue 
[4]. 
There are two forms of CoQ deficiency in humans, both resulting in 
mitochondrial dysfunction. Primary CoQ deficiency results from muta-
tions in CoQ biosynthetic genes and presents as a genetically and clin-
ically heterogenous disorder [5]. Secondary CoQ deficiency occurs 
without underlying genetic defects in CoQ biosynthesis, yet is strongly 
associated with aging, insulin resistance and cardiovascular diseases 
such as atherosclerosis, myopathy, and heart failure [6–11]. Preclinical 
studies have established that increasing tissue CoQ can decrease mito-
chondrial oxidant production, improve mitochondrial function, and can 
ameliorate disease. Unfortunately however, translating this knowledge 
into the clinic has remained challenging, principally due to our inability 
to effectively restore CoQ concentrations in most human tissues as a 
result of the low bioavailability of orally supplemented CoQ [12]. A 
better understanding of the endogenous systems that regulate tissue CoQ 
content beyond the biosynthetic genes may help overcome this current 
limitation and identify new strategies to enhance endogenous CoQ 
biosynthesis. 
Although CoQ was discovered more than 60 years ago, our under-
standing of how cells regulate their CoQ content has remained limited to 
individual factors required for optimal CoQ synthesis [13–15]. To date, 
a systemic approach aimed at identifying networks important for the 
regulation of cellular CoQ concentrations beyond the mevalonate 
pathway has not been carried out. A likely reason for this is the tech-
nically challenging nature of high-throughput CoQ extraction and 
analysis. To overcome this current limitation, we developed a 
large-scale screening method to analyze and quantify cellular CoQ using 
high-performance liquid chromatography coupled with electrochemical 
detection (HPLC-ECD). Using this platform, we used the Yeast Deletion 
Collection to conduct a genome-wide genetic screen and identified 30 
new potential CoQ-regulating genes. Of these, we focused on phospha-
tidylethanolamine N-methyltransferase (PEMT) that plays a key role in 
phospholipid metabolism. We observed that cells deficient in PEMT 
contain strikingly higher concentrations of mitochondrial CoQ in mul-
tiple biological systems. Using genetic manipulations, lipidomics, and 
untargeted and targeted metabolomics, we discovered a previously un-
recognized link between endoplasmic reticulum/mitochondrial associ-
ated membrane PEMT activity, and the mitochondrial methylation 
activity required for CoQ synthesis. Finally, we identified increased 
mitochondrial CoQ as the molecular basis for how PEMT deficiency 
protects mice against insulin resistance. 
2. Methods 
2.1. Genome-wide screen of mutants with altered total CoQ6 content 
The homozygous diploid yeast knockout collection (BY4743; Euro-
scarf) was used to screen genes that affected total CoQ6 content. The 
collection is housed in a series of 96-well plates kept frozen at − 80 ◦C. 
Briefly, cells were inoculated from − 80 ◦C stocks with 2.4 μL of 
defrosted culture inoculated into 96-well plates containing 195 μL 
media. Cells were grown for 2 d at 30 ◦C with shaking. After 2 d, 2.4 μL 
of pre-culture was inoculated into 96-well plates containing 195 μL fresh 
media and cells were grown for 18 h at 30 ◦C with shaking. After 18 h, 
the OD600 was measured (Pherastar 96-well plate spectrophotometer) 
and the plate centrifuged (1500×g; 4 ◦C; 5 min) to pellet cells. 190 μL of 
supernatant was removed from each well and the cell pellet in each well 
resuspended in 50 μL of 155 mM ammonium acetate. The 96-well plate 
was frozen at − 20 ◦C until CoQ6 extraction and analysis. On the day of 
analysis, plates were defrosted and 50 μL of cell suspension was trans-
ferred to a glass-coated 96 deep-well plate containing 50 μL of glass 
beads per well. As a control, a separate batch of WT cells grown to OD600 
~1.0 and frozen in aliquots were used as quality control (QC) samples in 
each plate. Wells A1, E6 and H12 of each plate were used for the QC 
samples with 50 μL of QC sample put in each well on the day of analysis. 
For each plate to pass ‘QC’, the CoQ6 content of the QC wells had to be 
within 20% of each other. Cells were lysed and CoQ6 extracted and 
analyzed as outlined below. 
2.2. Determination of CoQ6 and ergosterol content in yeast cells 
The method used was adapted from Gay & Stocker 2004 [16]. 50 μL 
0.155 mM ammonium acetate was added to yeast cell pellets and the 
suspension was transferred to a glass-coated 96 deep well plate con-
taining 50 μL glass beads per well. Cells were lysed using a Thermomixer 
C (Eppendorf, 1400 rpm, 2 h, 4 ◦C). 200 μL of acidified methanol and 
500 μL water-washed hexane was added to each sample, and the plate 
shaken (1000 rpm, 1 min, 4 ◦C). 300 μL of the hexane layer was removed 
and 500 μL hexane added, and the plate re-shaken (1000 rpm, 1 min, 
4 ◦C). This was repeated five times with 800 μL hexane removed on the 
fifth repeat (a total of 2 mL hexane collected). The collected hexane was 
dried under nitrogen in a fume hood for 1 h at room temperature. The 
resulting dried lipids were re-dissolved in 150–180 μL ice-cold mobile 
phase (ethanol:methanol:isopropanol: ammonium acetate pH 4.4, 
65:30:3:2, vol/vol/vol/vol) and transferred into HPLC vials. Samples 
were stored at 4 ◦C until analysis via HPLC coupled to UV and electro-
chemical detection (HPLC-UV/ECD) or liquid chromatography tandem 
mass spectrometry (LC-MS/MS). For HPLC-UV/EC analyses, 100 μL of 
samples were injected onto a Supelcosil LC-C18 column (5 μm, 250 mm 
× 4.6 mm) eluted at 1 mL/min and connected to UV and electrochemical 
(ESA CoulArray 5600A) detectors. Ergosterol was detected at 280 nm, 
while total CoQ6 (CoQ6 + CoQ6H2) was detected at − 700, +700 and +
700 mV. For studies in which total CoQ6 (CoQ6 + CoQ6H2) was deter-
mined by LC-MS/MS, 2 μL of sample was injected onto an Agilent 1290 
UHPLC system connected to an Agilent 6490 triple-quadrupole mass 
spectrometer. Analytes were separated on a Luna 5 μm C18 (2) 100 Å 
column (150 × 4.6 mm; Phenomenex, USA) by gradient elution using 
mobile phase A (2.5 mM ammonium formate in 95:5 methanol:iso-
propanol) and mobile phase B (2.5 mM ammonium formate in 100% 
isopropanol) at 0.4 mL/min. The gradient consisted of 50% mobile 
phase B from 0 to 15 min, 50–70% B from 15 to 17 min, 100% B from 17 
to 19 min and back to 50% B from 19 to 24 min. Flow was then directed 
into the triple quadrupole mass spectrometer with parameters set as 
follows: gas temperature = 290 ◦C; gas flow = 14 L/min; nebuliser 
pressure = 25 psi; sheath gas heater = 400 ◦C; sheath gas flow = 11 
L/min; capillary voltage = 3000 V. Detection of CoQ6, was by multiple 
reaction monitoring (MRM) in positive ion mode using the above gen-
eral mass spectrometry parameters with fragmentor voltage at 380 V 
and cell accelerator voltage at 5 V. The fragment ion generated by 
collision-induced dissociation of the [M + H]+ ion was used for quan-
tification. MRM settings for the target analytes were (parent ion → 
fragment ion); CoQ6 (m/z 591.3.1 → 197.1) with collision energy of 21 V 
and CoQ6H2 (m/z 593.3.1 → 197.1) with collision energy of 25 V. CoQ6, 
CoQ6H2 and ergosterol were quantified against authentic commercial 
standards obtained from Avanti Polar Lipids and Sigma Aldrich (USA) 
respectively. 
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2.3. Determination of S-adenosyl-L-methionine and S-adenosyl-L- 
homocysteine content in yeast cells and mitochondria 
All work was carried out under an argon gas cloud. Yeast pellets were 
defrosted and 100 μL of 50% methanol containing 100 μM diethylene-
triaminepentaacetic acid (DTPA) was added and cell pellets lysed at 40 
kpsi (50 s on, 10 s off; 30 cycles at 20 ◦C) using a Barocycler 2320EXT 
(Pressure BioSciences Inc). 100 μL chloroform containing 100 μM DTPA 
was added to the lysate, the suspension mixed vigorously for 1 min, 
centrifuged (5000×g, 5 min, 4 ◦C), and 50 μL top aqueous layer removed 
and 100 μL 50% methanol containing 100 μM DTPA added to the 
sample. The sample was vortexed for 1 min, centrifuged (5000×g, 5 min, 
4 ◦C), and 100 μL of the aqueous layer removed (total 150 μL sample 
collected). Samples were stored at − 80 ◦C until analysis. 5 μL of sample 
was injected onto an Agilent 1290 UHPLC system connected to an Agi-
lent 6490 triple-quadrupole mass spectrometer. Analytes were separated 
on a Polar RP 80 Å column 250 × 2.5 mm (Phenomenex, USA) by 
gradient elution using mobile phase A (0.1% formic acid, 5 μM medronic 
acid in water) and mobile phase B (0.1% formic acid, 5 μM medronic 
acid in 100% methanol) at 0.2 mL/min. The gradient consisted of 2% 
mobile phase B from 0 to 5 min, 2–90% B from 10 to 15 min, 2% B from 
15 to 18 min. Flow was then directed into the triple quadrupole mass 
spectrometer with parameters set as follows: gas temperature = 220 ◦C; 
gas flow = 12 L/min; nebuliser pressure = 40 psi; sheath gas heater =
380 ◦C; sheath gas flow = 12 L/min; capillary voltage = 4000 V. 
Detection of SAM and SAH was by multiple reaction monitoring (MRM) 
in positive ion mode using the general mass spectrometry parameters 
listed above with fragmentor voltage at 380 V and cell accelerator 
voltage at 4 V. The fragment ion generated by collision-induced disso-
ciation of the [M + H]+ ion was used for quantification. MRM settings 
for the target analytes were (parent ion → fragment ion); SAM (m/z 
399.4 → 249.9) with collision energy of 17 and SAH (m/z 385.4 → 
136.0) with collision energy of 25. SAM and SAH were quantified 
against commercial standards (Sigma-Aldrich). 
For mitochondrial analyses of SAM and SAH, yeast mitochondria 
were isolated as described [17]. Briefly, cells were grown until; OD600 
~1.0 and centrifuged (3000×g, 5 min, 4 ◦C) to pellet cells. Cells were 
resuspended in 100 mM Tris-H2SO4 buffer pH 9.4 containing 10 mM 
dithiothreitol (DTT) and incubated at 30 ◦C for 20 min. Cells were 
centrifuged at 3000×g for 5 min at 4 ◦C and resuspended in Zymolyase 
buffer (10 mM potassium phosphate pH 7.4, 1.2 M sorbitol). Cells were 
centrifuged (3000×g, 5 min, 4 ◦C), the supernatant removed, and pellets 
resuspended in Zymolyase buffer containing Zymolyase 100T and 
incubated at 30 ◦C shaking for 1 h. Following washing with Zymolyase 
buffer, cells were resuspended in homogenization buffer (10 mM Tris-Cl 
pH 7.4, 0.6 M sorbitol, 1 mM EDTA, 1 mM PMSF, 0.2% (w/v) bovine 
serum albumin (BSA)) and homogenized with 15 strokes of a 
Teflon-glass homogenizer. Following removal of cell debris by 
low-speed centrifugation (1500×g, 5 min, 4 ◦C), the supernatant was 
centrifuged at 4000×g for 5 min at 4 ◦C and the resulting supernatant 
centrifuged at 12,000×g for 15 min at 4 ◦C. The resulting mitochondrial 
pellet was gently resuspended in yeast mitochondrial buffer (1 mM 
MOPS-KOH pH 7.2, 250 mM sucrose). Protein concentration was 
determined by BCA assay as per manufacturer’s protocol (ThermoFisher 
Scientific) and samples stored at − 20 ◦C until analysis. On the day of 
analysis, 50 μg mitochondrial protein was resuspended in 100 μL of 50% 
methanol containing 100 μM DTPA and extracted as per yeast homog-
enates, and SAM and SAH concentrations determined by LC-MS/MS as 
outlined above. 
2.4. McArdle-RH7777 hepatoma cell culture 
Rat McArdle-RH7777 hepatoma cells stably transfected with a vector 
containing human PEMT [18] were grown in Dulbecco’s Modified Eagle 
Medium (DMEM, Thermo Fisher Scientific, 11995) containing 10% fetal 
calf serum (FCS), 4.5 g/L glucose, 110 mg/L sodium pyruvate, 1X 
GlutaMAX™ (ThermoFisher Scientific) supplemented with penicillin 
and streptomycin in a humidified atmosphere with 5% CO2. Cells were 
incubated with 10 μM 3-deazaadenosine (DZA) or vehicle (water) for 24 
h and cells were harvested and stored at − 20 ◦C until mitochondrial 
CoQ, SAM and SAH were determined as outlined previously. 
2.5. 3T3-L1 fibroblast culture and differentiation into adipocytes 
Mycoplasma-free 3T3-L1 fibroblasts obtained from Howard Green 
(Harvard Medical School, Boston, MA) were maintained in Dulbecco’s 
Modified Eagle Medium (DMEM) (Thermo Fisher Scientific, 11995) 
supplemented with 10% FCS (Thermo Fisher Scientific), 1% Gluta-
MAX™ (Thermo Fisher Scientific) in a humidified atmosphere with 5% 
CO2. Confluent 3T3-L1 cells were differentiated into adipocytes by the 
addition of DMEM supplemented with 10% FSC and 0.22 μM dexa-
methasone, 100 ng/mL biotin, 2 μg/mL insulin and 500 μM 3-isobutyl-1- 
methylxanthine (day zero). After 72 h, medium was replaced with 
DMEM/10% FCS/GlutaMAX™ containing 2 μg/mL insulin (day three 
post differentiation) and grown for a further 72 h (day six post differ-
entiation). Cells were used between days 6 and 7 after the initiation of 
differentiation for all experiments. 
2.6. Determination of CoQ content in differentiated 3T3-L1 adipocytes 
and McArdle RH7777 hepatoma cells 
Briefly, cells were homogenized in mitochondrial isolation buffer 
(10 mM Tris-MOPS, pH 7.4, 1 mM EGTA, 200 mM sucrose containing 
protease inhibitors) for 30 s at 7000 rpm (Heidolph homogenizer) and 
samples kept at 4 ◦C subsequently. 100 μL of the homogenates was kept 
for total tissue CoQ9 and CoQ10 analyses, and the remaining homogenate 
was used to isolate mitochondria as previously described [19]. Briefly, 
homogenates were centrifuged at 700×g for 10 min and the supernatant 
isolated and centrifuged at 7000×g for 10 min to obtain a pellet con-
taining the mitochondria. The pellet was re-suspended in mitochondrial 
isolation buffer and re-centrifuged at 7000×g for 10 min. The mito-
chondrial pellet was finally re-suspended in mitochondrial isolation 
buffer and protein concentration determined using the BCA assay. CoQ 
extraction was carried out as previously described [16]. Briefly, 50–100 
μL of isolated mitochondria was incubated with 25 μL para--
benzoquinone (2 mg/mL) for 30 min at room temperature, and 2 mL 
acidified methanol and 10 mL of water-washed hexane were added. The 
mixture was mixed vigorously for 1 min, centrifuged (1430×g, 5 min, 
4 ◦C) and 9 mL of hexane layer collected and dried using a rotary 
evaporator. The resulting dried lipids were re-dissolved in 150–180 μL 
ice-cold mobile phase (ethanol:methanol:isopropanol: ammonium ace-
tate pH 4.4, 65:30:3:2, vol/vol/vol/vol), transferred into HPLC vials and 
analyzed using HPLC connected to UV and electrochemical detectors as 
outlined above, or using liquid chromatography tandem mass spec-
trometry (LC-MS/MS). If LC-MS/MS was used, the dried lipids were 
resuspended in 150 μL ice-cold HPLC-grade ethanol and analyses carried 
out as per described previously [11]. 
2.7. Determination of S-adenosyl-L-methionine and S-adenosyl-L- 
homocysteine content in liver 
Mitochondria from liver tissue was extracted as previously described 
for mitochondrial CoQ determination. Mitochondrial pellets were 
resuspended in 100 μL mitochondrial isolation buffer (10 mM Tris- 
MOPS, pH 7.4, 1 mM EGTA, 200 mM sucrose containing protease in-
hibitors) and stored at − 20 ◦C until analysis. 50 μL of liver mitochondria 
were defrosted and 50 μL of 100% methanol containing 100 μM DTPA 
was added to mitochondria. 100 μL chloroform containing 100 μM 
DTPA was added to the sample and the suspension mixed vigorously for 
1 min, centrifuged (5000×g, 5 min, 4 ◦C). 50 μL of the top aqueous layer 
was removed and 100 μL 50% methanol containing 100 μM DTPA added 
to the sample. The sample was vortexed for 1 min, centrifuged (5000×g, 
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5 min, 4 ◦C), and 100 μL of the aqueous layer removed (total 150 μL 
sample collected). All sample work up was done under a cloud of argon 
gas. Samples were stored at − 80 ◦C until analysis. 5 μL of sample was 
injected onto an TSQ Altis™ Triple Quadrupole Mass Spectrometer 
(ThermoFisher Scientific). Analytes were separated on a Polar RP 80 Å 
column 250 × 2.5 mm (Phenomenex, USA) by gradient elution using 
mobile phase A (0.1% formic acid, 5 μM medronic acid in water) and 
mobile phase B (0.1% formic acid, 5 μM medronic acid in 100% meth-
anol) at 0.2 mL/min. The gradient consisted of 2% mobile phase B from 
0 to 5 min, 2–90% B from 10 to 15 min, 2% B from 15 to 18 min. The 
triple quadrupole mass spectrometer H-ESI source parameters were set 
as follows: sheath gas = 58.8 Arb, aux gas = 13.4 Arb, sweep gas = 2.9 
Arb, Ion transfer tube temperature = 350 ◦C, static spray voltage with 
positive ion voltage set at 4936.36 V and negative ion voltage set at 
3500 V. Detection of SAM and SAH, was by multiple reaction monitoring 
(MRM) in positive ion mode using the above general mass spectrometry 
parameters. The fragment ion generated by collision-induced dissocia-
tion of the [M + H]+ ion was used for quantification. MRM settings for 
the target analytes were (parent ion → fragment ion); SAM (m/z 
399.088 → 136.125) with collision energy of 27.03 and RF lens 64 V, 
SAH (m/z 385.088 → 134.042) with collision energy of 19.49 and RF 
lens 58 V. SAM and SAH were quantified against commercial standards 
(Sigma-Aldrich). For samples analyzed on the TSQ Altis™ Triple 
Quadrupole Mass Spectrometer, data was analyzed using Thermo Fisher 
Scientific™ FreeStyle software. 
2.8. Animal studies 
All animal procedures were approved by the University of Alberta’s 
Institutional Animal Care Committee (AUP00000175) in accordance 
with guidelines of the Canadian Council on Animal Care. Mice were 
exposed to a 12-h light/dark cycle with free access to food and drinking 
water. Male Pemt+/+ and Pemt–/– (C57BL/6J) mice were fed a standard 
chow diet (5001; LabDiet, St. Louis, MO, USA) or a semisynthetic high- 
fat diet (HFD, F3282; Bio-Serv, Flemington, NJ, USA) that contained 60 
kcal% from lard. Mice were kept on the appropriate diet for 6–10 weeks 
and tissue collected and stored at − 80 ◦C until analyses. As previously 
reported (20), for in vivo experiments using control (GFP) adeno- 
associated virus (AAV.GFP) and PEMT expressing adeno-associated 
virus (AAV.PEMT) [20], Pemt–/– mice were injected with 1 × 1010 
genome copies per mouse of AAV.GFP or AAV.PEMT, and Pemt+/+ mice 
were injected with an equal dose of AAV.GFP. At 1-week post-AAV 
administration mice, were fed HFD for 10 weeks [20]. For in vivo anti-
sense oligonucleotide (ASO) experiments, male C57BL/6J mice (pur-
chased from Jackson Laboratory, Bar Harbor, ME, USA) were 
intra-peritoneally injected weekly (25 mg/kg b.w.) with either a 
scrambled control ASO (5′-GGCCAATACGCCGTCA-3′) or an ASO that 
inhibits PEMT (5′-CTTTATTAGTGTGTCG-3′), (5′-TTATTAGTGTGTC 
GGG-3′) or (5′-ACAACATGATTGGACC-3′) provided by Ionis Pharma-
ceuticals). One week after the first ASO injection, mice were fed the HFD 
for 10 weeks and tissue collected and stored at − 80 ◦C until analyses. 
Glucose tolerance tests, insulin tolerance tests and PEMT activity assays 
in mice treated with ASO were carried out as previously described [20]. 
For glucose tolerance test data, area under the curve was computed 
using the trapezoid rule. For insulin tolerance test data, incremental area 
under the curve was computed. For this, each data point was baseline (0 
time) corrected and Δ blood glucose was plotted over time. The area 
under the Δ blood glucose curve was then calculated using the trapezoid 
rule. 
2.9. Determination of CoQ9 and CoQ10 content in mouse tissue and 
mitochondria 
Tissues were homogenized in mitochondrial isolation buffer (10 mM 
Tris-MOPS, pH 7.4, 1 mM EGTA, 200 mM sucrose containing protease 
inhibitors) for 30 s at 7000 rpm (Heidolph homogenizer) and samples 
kept at 4 ◦C for all subsequent procedures. 100 μL of the homogenates 
was kept for total tissue CoQ9 and CoQ10 analyses, and the remaining 
homogenate was used to isolate mitochondria as previously described 
[19]. Briefly, homogenates were centrifuged at 700×g for 10 min, the 
supernatant isolated and centrifuged at 7000×g for 10 min to obtain a 
pellet containing mitochondria. The pellet was re-suspended in mito-
chondrial isolation buffer and re-centrifuged at 7000×g for 10 min. The 
mitochondrial pellet was finally re-suspended in mitochondrial isolation 
buffer and a BCA assay (Thermo Fischer Scientific) carried out to 
quantify protein concentration. 50–100 μL of homogenate or isolated 
mitochondria was placed in a 15 mL screw top tube, 25 μL para--
benzoquinone (2 mg/ml) was added, incubated for 30 min at room 
temperature and then 2 mL ethanol: isopropanol (95:5) and 10 mL of 
water-washed hexane were added. The mixture was mixed vigorously 
for 1 min, centrifuged (1430×g, 5 min, 4 ◦C) and 9 mL of hexane was 
collected and dried using a rotary evaporator. The resulting dried lipids 
were re-dissolved in 150–180 μL ice-cold mobile phase (ethanol:meth-
anol:isopropanol: ammonium acetate pH 4.4, 65:30:3:2, vol/vol/vol/-
vol) and transferred into HPLC vials. Cholesterol, CoQ9 and CoQ10 were 
determined by HPLC using a Supelcosil LC-C18 column (5 μm, 250 mm 
× 4.6 mm) eluted at 1 mL/min connected to UV and electrochemical 
(ESA CoulArray 5600A) detectors. Non-esterified cholesterol was 
detected at 214 nm, while CoQ9 and CoQ10 were detected at − 700, +700 
and + 700 mV and quantified against authentic commercial standards 
obtained from Sigma Aldrich (USA). 
3. Results 
3.1. Genome-wide screening identifies 30 novel regulators of CoQ content 
To systematically identify the genetic networks controlling CoQ 
synthesis we conducted a quantitative genome-wide screen of all 5420 
mutants contained in the Saccharomyces cerevisiae homozygous diploid 
Deletion Collection [21]. This approach represents an unbiased, global 
approach to interrogate the CoQ regulatory framework by identifying 
gene deletions that alter cellular CoQ concentration. To enable 
large-scale screening by quantitative HPLC coupled to electrochemical 
detection, we developed an optimized method for cell growth, lysis and 
CoQ extraction for small culture volumes (~200 μL) in a 96-well plate 
format (Figs. S1A–C). Intra- and inter-day reproducibility of the method 
was 3 and 15%, respectively (Fig. S1D), and considered acceptable. The 
development of this screening method also increased the number of 
samples processed in one day by about five-fold, from 20 to 96. We then 
used this method to determine the cellular CoQ concentration in each 
knockout mutant, with results normalized to cell biomass. The screen 
was carried out in two phases (Fig. S2A). In both phases cells were 
grown in minimal media in the absence of any CoQ precursors such as 
para-aminobenzoic acid or 4-hydroxybenzoic acid to reduce confound-
ing results caused by substrate availability. First, all mutants were 
screened (n = 1), identifying 140 mutants with CoQ content 2 standard 
deviations higher or lower than the plate population mean. Second, 
these mutants were re-screened (n = 4–6) against wild-type (WT) cells to 
confirm gene mutants with significantly altered CoQ content. The ge-
netic screen revealed 30 mutants with significantly higher CoQ (‘high 
CoQ’) and seven with significantly lower CoQ (‘low CoQ’) than WT 
(Table 1). The ‘low CoQ’ mutants were comprised entirely of known 
genes of the biosynthetic pathway, as well as HFD1 which encodes a 
dehydrogenase involved in the production of the CoQ precursor, 
4-hydroxybenzoic acid [22]. These results validate the approach chosen 
to identify mutants with altered cellular CoQ content. The 30 ‘high CoQ’ 
mutants identified were comprised entirely of genes not previously 
associated with cellular CoQ and represent potential novel CoQ 
regulators. 
We next asked whether the identified 30 ‘high CoQ’ regulators form 
part of a transcriptional response to altered CoQ by studying the tran-
scriptional profiles of yeast mutants of the CoQ biosynthetic pathway 
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(coq1Δ, coq3Δ, coq7Δ, coq8Δ and coq9Δ) grown in the absence and 
presence of exogenously supplemented CoQ. Gene expression changes in 
mutants compared to WT (≥2-fold change) were identified. (Supple-
mentary Table 1). Notably, deficiency in any one of the COQ genes did 
not lead to the alteration of the expression of other COQ genes for the 
biosynthesis of CoQ. Of all mutants tested, only deletion of COQ7 
resulted in downregulation of COQ1 gene expression, with no COQ 
transcripts differentially expressed in any other mutant. There was also 
no change in the expression of genes identified in our screen, genes 
previously known to contribute to CoQ synthesis, such as PTC7 and 
HFD1, or genes involved in isoprenoid or benzoquinone head group 
synthesis. Comparing gene expression profiles across all COQ mutants 
(Figs. S2B–C), only 5 genes were identified as differentially expressed in 
the absence of CoQ supplementation (ARN2, FIT2, FIT3, FDC1 and 
YDR514C) and 7 genes in CoQ supplemented conditions (ARN1, ARN2, 
FIT2, PHO84, SIT1, TIS11 and YDR514c). 
Strikingly, the transcriptional changes observed in the various coq 
mutants were not able to be completely reversed by exogenous CoQ 
supplementation (Supplementary Table 1; Fig. S2C). Thus, exogenous 
CoQ supplementation may not be able to fully replace endogenous CoQ 
functions. In addition, CoQ supplementation did not lead to changes in 
any genes identified in our study, such as CHO2 or genes identified 
previously such as HFD1. From this it appears that exogenous CoQ 
supplementation does not, at least transcriptionally, affect endogenous 
CoQ regulatory pathways. 
3.2. A deficiency in phosphatidylethanolamine (PE) methylation results 
in increased mitochondrial CoQ 
Among the top hits was the cho2Δ mutant which lacks PEMT, 
encoded by the CHO2 gene. The methylation pathway is one of three 
distinct PC synthesis pathways, along with the Kennedy Pathway and 
lyso-PC to PC cycling (Fig. 1A). We focused on the cho2Δ mutant for the 
following reasons. First, PEMT activity is evolutionarily conserved in 
eukaryotes. Second, mice lacking PEMT are viable and have long been 
known to be protected from atherosclerosis, age-dependent cardiac 
dysfunction and insulin resistance [23–25], although the underlying 
reasons for this protective phenotype have remained obscure. Third, 
PEMT catalyzes the methylation of phosphatidylethanolamine (PE) to 
phosphatidylcholine (PC), and CoQ biosynthesis requires three 
methylation steps. Finally, a potential link between PEMT and CoQ has 
not been investigated to date. 
The cho2Δ mutant accumulated five times more total CoQ than WT 
cells (Fig. 1B) and over ten times more mitochondrial CoQ than WT cells 
(Fig. 1C). Consistent with this, the cho2Δ mutant displayed significantly 
increased concentrations of the CoQ6 intermediates demethoxy- 
demethyl-Q6 (DDMQ6), demethoxy-Q6 (DMQ6) and imino-demethoxy- 
Q6 (IDMQ6) (Fig. 1D–F). The cho2Δ-CoQ relationship was confirmed in 
multiple yeast strain backgrounds (Figs. S3A and S3B). Mutants het-
erozygous for CHO2 did not have altered total or mitochondrial CoQ 
content (Figs. S3C and S3D). The observed increase in cellular CoQ in 
cho2Δ was reversed by re-expression of CHO2 (Fig. 1G), indicating that 
CoQ content is dependent on CHO2 expression. Isotope tracing studies 
using 13C6-4-hydroxybenzoic acid showed that cho2Δ cells have an 
increased rate of CoQ biosynthesis (Fig. 1H). These results establish that 
CHO2 deficiency is a positive regulator of mitochondrial CoQ content. 
3.3. PEMT deficiency increases mitochondrial CoQ through a 
phosphatidylcholine-independent pathway 
In yeast, conversion of PE to PC is carried out by two enzymes (Cho2 
and Opi3) [26], whereas in mammals PEMT catalyzes all three 
methylation reactions [27]. Consistent with previous reports, cho2Δ 
mutants had decreased PC (~2-fold) and increased PE concentrations 
(~1.5-fold) compared to WT cells [28,29] reflecting the role of CHO2 in 
PC synthesis (Figs. S3E–G). To test whether altered cellular PC content 
was responsible for increased CoQ in the cho2Δ mutant, cho2Δ cells were 
supplemented with choline to bypass defects in the methylation 
pathway [28]. This significantly elevated PC concentrations, normalized 
PE contents (Figs. S3E–F) and restored WT CoQ concentrations (Fig. 1I), 
consistent with cellular PC or the PC-to-PE ratio regulating CoQ con-
centrations. Inconsistent with this interpretation, however, supple-
mentation with monomethylethanolamine (MME) also restored WT CoQ 
content in cho2Δ (compare control in Fig. 1I with Fig. S3H) without 
restoring WT PC-to-PE ratios [28]. Moreover, the opi3Δ mutant, which 
lacks the ability to catalyze the last two methylation steps in PE for-
mation from PC, had significantly lower PC and similar PC-to-PE ratios 
compared with cho2Δ cells (Fig. S3G and S3I-K), yet accumulated ~ 
four-times less mitochondrial CoQ than cho2Δ cells (Fig. S3L). Mutants 
of the Kennedy pathway also did not have altered CoQ content despite 
having PC/PE ratios comparable to the cho2Δ mutant (Fig. 1J and K). 
Together, these results indicate that CHO2/PEMT modulates cellular 
CoQ independent of changes in PC and PE content, or changes to the 
PC-to-PE ratio. 
3.4. Mitochondrial CoQ is selectively altered in response to PEMT 
deficiency 
Mitochondrial CoQ synthesis requires three distinct building blocks 
(Fig. S4A): the ‘benzoquinone ring’ derived from a tyrosine/ring pre-
cursor; the polyisoprenoid ‘tail’ derived from the mevalonate pathway; 
and a methyl donor S-adenosylmethionine (SAM) required to produce 
Table 1 
S. cerevisiae mutants identified with significantly decreased or increased CoQ6 
content compared with WT.  
‘Low CoQ’ mutants  
~Fold decrease in CoQ6 vs WT 
coq2Δ not detectable 
coq3Δ not detectable 
coq4Δ not detectable 
coq6Δ not detectable 
coq8Δ not detectable 
coq9Δ not detectable 
hfd1Δ 2 
‘High CoQ’ mutants  


























rrg7 Δ 7 
cdc50Δ 8 
ric1Δ 11 
ort1 Δ 11 
adk1 Δ 12  
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the fully substituted benzoquinone ring in CoQ. These building blocks 
are transported from the cytosol into mitochondria where the synthesis 
of CoQ takes place. To determine if increased CoQ biosynthesis in cho2Δ 
cells could be explained by a simple increase in mitochondria that 
provide the ‘machinery’ for CoQ biosynthesis, mitochondrial mass was 
assessed by four independent assays: mitochondrial DNA, citrate syn-
thase activity, porin content, and oxygen flux (Figs. S4B–E). All four 
parameters showed only a modest increase in mitochondrial mass in 
cho2Δ, well below the 10-fold increase in mitochondrial CoQ. We next 
asked whether mevalonate-derived lipids were altered. Untargeted lip-
idomics analyses revealed an increase in dolichols in cho2Δ (Fig. S4F) in 
parallel with an increase in expression of genes involved in the dolichol 
synthesis pathway (Fig. S4G). This suggested flux through the mevalo-
nate pathway may be altered. However, concentrations of ergosterol 
(the yeast equivalent of mammalian cholesterol) were not altered in 
cho2Δ (Fig. S4H), indicating that it is unlikely an increase in mevalonate 
pathway flux or farnesyl pyrophosphate availability underpins the al-
terations in CoQ and dolichols in cho2Δ. Supporting this, there was no 
change in the expression of farnesyl diphosphate synthase (ERG20), or 
the genes of the mevalonate pathway in cho2Δ (Fig. S4I), indicating 
differential regulation of isoprenoid lipids by CHO2. Finally, the 
increased rate of CoQ biosynthesis was observed in the absence of 
changes in the transcript or protein levels of presently known members 
of the CoQ biosynthetic ‘machinery’ [30] (Figs. S5A–B), although cho2Δ 
displayed a more stabilized CoQ-synthome (Fig. S5C). The stabilization 
of the CoQ synthome is an intriguing observation and a direct interac-
tion between Cho2p and the CoQ synthome may exist. However, we 
believe it is more likely that lack of CHO2 indirectly acts to stabilize the 
complex by virtue of increasing CoQ content which has been shown to 
stabilize some Coq polypeptides and potentially stabilize the CoQ syn-
thome [31]. 
3.5. PEMT deficiency increases CoQ biosynthesis via increasing 
mitochondrial methylation capacity 
To further understand how a deficiency in cho2 increases mito-
chondrial CoQ, we performed untargeted metabolomic analyses. This 
identified numerous metabolites significantly altered in cho2Δ 
compared with WT cells (Fig. 2A and B; Figs. S6A–B), with the greatest 
differences observed in S-adenosylmethionine (SAM) and S-adeno-
sylhomocysteine (SAH) (Fig. S6C). Whole-cell SAM was increased while 
SAH concentrations were decreased in cho2Δ, as reported previously 
[32]. Targeted LC-MS/MS analyses confirmed these results (Fig. 2C and 
D). Deficiencies in methyltransferases other than cho2 had no effect on 
cellular CoQ, SAM and SAH (Figs. S6D–F). Strikingly, mitochondrial 
SAM and SAH concentrations were both increased in cho2Δ (Fig. 2E and 
F), in sharp contrast to the situation in whole cells. As CoQ biosynthesis 
requires SAM-dependent methylation of the benzoquinone ring, WT 
cells were supplemented with the SAM precursor methionine. This 
caused a ~20-fold increase in cellular and mitochondrial SAM 
(Figs. S7A–B) yet CoQ was unaffected (Fig. S7C). Methionine supple-
mentation also increased cellular and mitochondrial SAM concentra-
tions in cho2Δ mutants, and in this case, CoQ decreased significantly 
(Fig. S7C). Together, these results show that cellular or mitochondrial 
SAM concentrations alone do not determine CoQ concentrations. 
SAH is a product inhibitor of methyltransferase activity, and the 
SAM-to-SAH ratio (rather than SAM concentrations alone) is considered 
to reflect methylation potential. Compared with WT cells, cho2Δ mu-
tants had increased cellular and mitochondrial SAM-to-SAH ratios 
(Fig. 2G) in parallel with increased CoQ. In WT cells, methionine sup-
plementation increased cellular and mitochondrial SAH (Figs. S7D–E) to 
an extent comparable to that of SAM (Figs. S7A–B), such that there was 
no change the SAM-to-SAH ratio (Fig. S7F). In cho2Δ cells, methionine 
supplementation had no effect on cellular SAH (Fig. S7D), whereas it 
significantly increased mitochondrial SAH concentrations (Fig. S7E), 
such that the mitochondrial SAM-to-SAH ratio decreased (Fig. S7G) in 
parallel with decreased CoQ. These results suggest that it is the mito-
chondrial SAM-to-SAH ratio i.e., the methylation capacity of mito-
chondria that regulates mitochondrial CoQ, although it remains unclear 
why methionine supplementation differentially affects cellular and 
mitochondrial SAM and SAH pools. 
The methionine cycle, including SAM synthesis, takes place in the 
cytosol. Cytosolic SAM is then transported into mitochondria by SAM5 
which itself is inhibited competitively by SAH. As SAM5 expression was 
not altered in cho2Δ mutants (Fig. 2H), we reasoned that their higher 
mitochondrial SAM-to-SAH ratio reflected a proportionally higher up-
take of cytosolic SAM than SAH, thereby increasing the mitochondrial 
methylation capacity and, as a result, mitochondrial CoQ synthesis. To 
test this hypothesis, we overexpressed the SAM synthetase SAM1 in 
either the cytosol or mitochondria of WT cells. Strikingly, mitochondrial 
overexpression of SAM1 increased CoQ almost five-fold, whereas cyto-
solic overexpression of SAM1 did not change CoQ (Fig. 2I). These ob-
servations, together with the findings that i) increased mitochondrial 
SAM-to-SAH is a hallmark of cho2Δ and ii) decreasing this ratio de-
creases mitochondrial CoQ, indicate that the mitochondrial SAM-to-SAH 
ratio is a previously unrecognized key regulator of CoQ biosynthesis and 
mitochondrial CoQ content. 
3.6. PEMT deficiency regulation of mitochondrial CoQ concentrations in 
evolutionarily conserved 
The methylation pathway of PC synthesis is highly conserved in 
eukaryotes [33] and the impact of PEMT deficiency on phospholipids, 
triacylglycerols [29] and ceramides [34] (Figs. S8A–B) is mirrored in 
yeast and mammals. To test if the yeast phenotype was conserved across 
species, we investigated the effect of PEMT deficiency on mitochondrial 
CoQ in multiple rodent cell types in vitro and in vivo. Pharmacological 
inhibition of PEMT in PEMT-expressing McArdle 7777 rat hepatoma 
cells (PEMT-McA) with 3-deazaadenosine (DZA) [35] increased mito-
chondrial CoQ (Fig. 3A). In line with this, livers of Pemt–/– mice fed chow 
had a significantly increased total (Fig. S8C) and mitochondrial CoQ 
(Fig. 3B) compared with Pemt+/+ littermates. Plasma CoQ, and total and 
mitochondrial CoQ in skeletal muscle, kidney, brain and white adipose 
tissue were not changed (Fig. S8D-L), consistent with PEMT expression 
being limited to the liver in chow-fed animals [36]. Like the situation in 
yeast, PEMT deficiency did not alter hepatic expression of CoQ biosyn-
thetic pathway genes (Fig. S8M). Consumption of a high fat diet (HFD) 
doubled total (Fig. S9A) and mitochondrial CoQ (Fig. 3C) in Pemt–/– 
Fig. 1. PEMT deficiency is a novel regulator of mitochondrial CoQ6 content in S. cerevisiae. (A) Scheme of the three pathways that mediate phosphatidyl-
choline (PC) synthesis in yeast and mammals; red indicates genes in yeast, while blue indicates mammalian genes. (B) Total CoQ6 concentrations in cho2Δ mutants 
compared with WT (n = 5). (C) Mitochondrial CoQ6 concentrations in cho2Δ mutants compared with WT cells (n = 3). (D) Mitochondrial demethoxy-demethyl-Q6 
(DDMQ6) concentrations in cho2Δ mutants compared with WT cells (n = 3). (E) Mitochondrial demethoxy-Q6 (DMQ6) concentrations in cho2Δ mutants compared 
with WT cells (n = 3). (F) Mitochondrial imino-demethoxy-Q6 (IDMQ6) concentrations in cho2Δ mutants compared with WT cells (n = 3). (G) Total CoQ6 con-
centrations in WT and cho2Δ mutants harboring either control vector or a single copy of CHO2 (n = 4). (H) CoQ6 biosynthetic rate in cho2Δ mutants and WT cells 
measured using the rate of 13C6-CoQ6 formed from supplemented 13C6-4-hydroxybenzoic acid (4HB) (n = 3). (I) Total CoQ6 concentrations in WT and cho2Δ mutants 
with or without 1 mM choline supplementation (n = 8). (J) Total CoQ6 concentrations in WT and mutants of the Kennedy Pathway (n = 5). (K) PC/PE ratio in WT 
and mutants of the Kennedy Pathway (n = 5). Data and error bars depict mean ± s.e.m. *depicts P ≤ 0.05 and ns indicates ‘not significant’ as determined by Mann- 
Whitney (B–F, H) or Kruskal-Wallis (G, I–K) test. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of 
this article.) 
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mice again without changes in the expression of CoQ biosynthetic 
pathway genes (Fig. S9B). Normalization of hepatic PEMT activity in 
Pemt–/– mice using an adeno-associated viral (AAV) system [20] 
decreased mitochondrial CoQ in the liver to that of Pemt+/+ animals 
expressing control GFP plasmid (Fig. 3D). These results show that PEMT 
expression regulates mitochondrial CoQ content in hepatic cell lines and 
the liver of mice, without apparent changes in the canonical CoQ 
biosynthetic pathway. 
We next investigated a potential role of PEMT in the regulation of 
CoQ concentration in non-hepatic cells. PEMT expression was induced 
during adipocyte differentiation (Fig. S9C), consistent with previous 
studies [37]. Inhibition of Pemt expression in 3T3-L1 adipocytes using 
anti-sense oligonucleotides (ASO; Fig. 3E) significantly increased mito-
chondrial CoQ (Fig. 3F). Moreover, we observed a significant increase in 
total (Fig. S9D) and mitochondrial CoQ (Fig. 3G) in white adipose tissue 
of Pemt–/– mice fed a high fat diet, conditions where PEMT expression is 
induced in adipose tissue [37]. Together, these results show that PEMT 
expression can regulate mitochondrial CoQ content in hepatocytes and 
adipocytes in vitro and in vivo, as observed in yeast. 
Fig. 2. PEMT deficiency increases CoQ biosynthesis via altering mitochondrial S-adenosylmethionine and S-adenosylhomocysteine in S. cerevisiae. (A) 
Principal component analyses (PCA) plots of metabolites identified in WT and cho2Δ in both positive and negative ionization modes. (B) Whole cell S-adeno-
sylmethionine (SAM) in WT and cho2Δ cells (n = 5). (C) Whole cell S-adenosylhomocysteine (SAH) in WT and cho2Δ cells (n = 5). (E) Mitochondrial SAM in WT and 
cho2Δ cells (n = 4). (F) Mitochondrial SAH in WT and cho2Δ cells (n = 4). (G) Whole-cell and mitochondrial SAM/SAH ratios in WT and cho2Δ cells (n = 4). (H) 
SAM5 gene expression in WT and cho2Δ mutants as measured by qPCR (n = 5). (I) The effect of overexpression of S-adenosylmethionine synthetase 1 (SAM1) either 
in the mitochondria (mito-SAM1) or cytosol (cyto-SAM1) compared to empty vector (EV) control on CoQ6 content in WT. # indicates significant difference between 
EV and mito-SAM1. Data and error bars depict mean ± s.e.m. *P ≤ 0.05 as determined by Mann-Whitney (A-H) or Kruskal-Wallis test (I). 
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3.7. Mitochondrial SAM-to-SAH ratio is a central feature of PEMT 
deficiency 
A previous commentary [38] suggested that hepatic PEMT was a 
major component of whole body SAM utilization. A separate investiga-
tion reported no difference in hepatic SAM and SAH concentrations in 
Pemt–-/– compared with Pemt+/+ mice [39] although mitochondrial SAM 
and SAH concentrations were not independently measured. We there-
fore examined whether PEMT expression regulated mitochondrial CoQ 
in liver through specific changes in the mitochondrial SAM-to-SAH ratio 
using the previously described AAV system. Compared with WT animals, 
livers from Pemt–/– mice expressing GFP (control) had significantly 
increased mitochondrial SAM-to-SAH ratio (Fig. 3H), paralleling their 
increase in mitochondrial CoQ (Fig. 3D). Expression of Pemt in Pemt–/– 
Fig. 3. PEMT deficiency increases mitochondrial CoQ content in mammalian cells and tissues. (A) Effect of inhibiting PEMT activity in PEMT-expressing 
McArdle 7777 hepatoma cells by 3-deazaadenosine (DZA) on mitochondrial CoQ9 content (n = 4). (B) Hepatic mitochondrial CoQ9 content in Pemt+/+ and 
Pemt–/– mice fed chow (n = 6). (C) Hepatic mitochondrial CoQ9 content in Pemt+/+ and Pemt–/– mice fed HFD for 6 weeks (n = 6–8). (D) Mitochondrial CoQ9 content 
in mice treated with adeno-associated virus (AAV) expressing Pemt or GFP control (n = 3–6). (E) Effect of anti-sense oligonucleotide (ASO) mediated knockdown of 
PEMT in differentiated 3T3-L1 adipocytes on PEMT gene expression as determined by qPCR (n = 4). (F) Mitochondrial CoQ9 content in differentiated 3T3-L1 
adipocytes treated with either control or anti-PEMT ASO (n = 4). (G) White adipose tissue mitochondrial CoQ9 content in Pemt+/+ and Pemt–/– mice fed HFD for 
6 weeks (n = 6–8) (H) Mitochondrial SAM/SAH ratio in mice treated with adeno-associated virus (AAV) expressing Pemt or GFP control (n = 3–6). Data and error 
bars depict mean ± s.e.m. *P ≤ 0.05 and ns indicates ‘not significant’ as determined by Mann-Whitney (A-C, E-G) or Kruskal-Wallis test (D, H). 
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mice decreased the mitochondrial SAM-to-SAH ratio to levels observed 
in Pemt+/+ mice, again in parallel with the observed normalization of 
mitochondrial CoQ (Fig. 3D). Thus, PEMT expression affects the 
SAM-to-SAH ratio in mitochondria. Together the data indicate that 
lowering PEMT expression is sufficient to increase both the mitochon-
drial SAM-to-SAH ratio and mitochondrial CoQ content, and this rela-
tionship is maintained in a broad range of species. 
3.8. PEMT deficiency protects against insulin resistance via modulating 
CoQ and decreasing mitochondrial oxidative stress 
We next examined whether regulating mitochondrial CoQ via PEMT 
can be exploited to ameliorate disease associated with CoQ deficiency. 
To do this, we focused on insulin resistance for three reasons. First, 
Pemt–/– mice are protected from insulin resistance [25,40] via a 
currently unexplained mechanism. Second, decreased mitochondrial 
CoQ is an up-stream driver of insulin resistance in humans, mice, and 
cellular models [11,41,42], and CoQ supplementation reverses insulin 
resistance. Third, increasing mitochondrial CoQ decreases mitochon-
drial superoxide [11] another upstream driver of insulin resistance. We 
therefore first examined the effect of PEMT deficiency on mitochondrial 
superoxide. Compared with WT cells, cho2Δ mutants had decreased 
mitochondrial superoxide, as assessed by MitoSOX fluorescence 
(Fig. S9E). Similarly, cho2Δ cells were also protected from decreased 
viability induced by polyunsaturated fatty acids (Fig. S9F), consistent 
with superoxide being the primordial reactive oxygen species that can 
give rise to cell damage via oxidation of unsaturated fatty acids. These 
results indicate that PEMT deficiency decreases mitochondrial oxidative 
stress. 
To more directly link mitochondrial CoQ and PEMT, we used anti-
sense oligonucleotide (ASO) technology in differentiated 3T3-L1 adi-
pocytes treated with tumour necrosis factor-α (TNFα) as a cellular model 
of insulin resistance [43]. Decreasing PEMT expression by ASO treat-
ment increased mitochondrial CoQ concentrations above that seen in 
control ASO-treated cells (Fig. 4A) without a change in 
insulin-stimulated 2-deoxyglucose uptake (Fig. 4B). Exposure of control 
ASO-treated adipocytes to TNFα decreased mitochondrial CoQ (Fig. 4A) 
and insulin-stimulated 2-deoxyglucose uptake (Fig. 4B). Similarly, 
pharmacological blockade of CoQ synthesis with 4-nitrobenzoic acid 
(4NB, a competitive inhibitor of 4-hydroxybenzoate:polyprenyltransfer-
ase) [44], decreased mitochondrial CoQ (Fig. 4A) in control ASO-treated 
cells to a comparable extent to that seen with TNFα treatment. This was 
associated with a comparable decrease in insulin-stimulated glucose 
uptake (Fig. 4B), consistent with a causal link between mitochondrial 
CoQ and insulin sensitivity [11]. Replacing control with anti-Pemt ASO 
restored mitochondrial CoQ and insulin-stimulated 2-deoxyglucose up-
take to control values in both TNFα- and 4NB-treated cells (Fig. 4A and 
B). The results suggest that enhanced CoQ biosynthesis is required for 
PEMT deficiency to improve glucose utilization in a cellular model of 
insulin resistance. 
Finally, we examined how improved insulin sensitivity in vivo via 
decrease in PEMT activity relates to the mitochondrial SAM-to-SAH 
ratio. Anti-Pemt ASO significantly decreased hepatic PEMT activity in 
mice fed HFD (Fig. 4C) and such mice had improved glucose clearance 
(Fig. 4D) and insulin sensitivity (Fig. 4E). This was evidenced by a 
decreased area under the curve (AUC) for the glucose tolerance test 
(GTT), and an increased incremental area under the curve (iAUC) for 
insulin tolerance test (ITT) (see Fig. S9G for baseline corrected ITT 
values). Improved glucose clearance and insulin sensitivity were asso-
ciated with an increase in mitochondrial CoQ, SAM and SAM-to-SAH 
ratio (Fig. 4F–H), recapitulating the situation in global Pemt–/– mice. 
Together, these data provide a mechanism for how PEMT deficiency 
ameliorates insulin resistance, i.e., by increasing mitochondrial SAM-to- 
SAH ratio and CoQ synthesis, a known driver of insulin resistance 
(Fig. 4I). 
4. Discussion 
This study outlines the discovery of PEMT deficiency as the first 
identified positive regulator of mitochondrial CoQ content in organisms 
from budding yeast to mammals. PEMT regulates CoQ concentrations 
via modulation of the mitochondrial SAM-to-SAH ratio that determines 
the methylation reactions required for CoQ biosynthesis. Changes in 
CoQ are not dependent on altering cellular SAM concentrations or the 
SAM-to-SAH ratio per se, but rather a case of modulating the balance of 
mitochondrial metabolites, i.e., the ‘right ratio in the right place’. This 
interplay between SAM and PEMT is independent of the cellular PE-to- 
PC ratio, and it establishes a previously unrecognized functional rela-
tionship between PEMT, mitochondrial one-carbon metabolism and 
CoQ synthesis. Our discovery has potential medical implication because 
increasing mitochondrial CoQ via PEMT knockdown decreases mito-
chondrial oxidative stress and it maintains insulin sensitivity in vivo. At a 
mechanistic level, the biological benefit of PEMT knockdown is affected 
by increasing mitochondrial CoQ and a resulting decrease in superoxide, 
two known key drivers of insulin resistance. Together, this work en-
hances our understanding of how cells regulate mitochondrial CoQ 
synthesis and how this may be translated to a conceptually novel 
approach to treat insulin resistance. 
Our key finding of PEMT as a conserved regulator of mitochondrial 
CoQ content is supported by work in budding yeast, mammalian cell 
culture models and in vivo mouse studies. Combining the classical ge-
netic approach of gene knockout and re-expression with targeted LC- 
MS/MS analysis, a direct relationship between PEMT expression and 
mitochondrial CoQ content was established. Significantly, re- 
introduction of PEMT expression normalized mitochondrial CoQ con-
centrations in both budding yeast and mouse models. Acute PEMT 
disruption mediated by small molecules such as 3-deazaadenosine or 
antisense oligonucleotides was also sufficient to increase mitochondrial 
CoQ, recapitulating the results from the genetic approach. Collectively 
these data confirm that modulation of PEMT at the gene, mRNA or 
enzyme activity level increases mitochondrial CoQ in a variety of 
species. 
Our studies establish that spatial compartmentalization of the one- 
carbon metabolites SAM and SAH in mitochondria is necessary for 
changes in CoQ concentrations and the underlying basis of the PEMT- 
CoQ relationship. Use of untargeted ‘global’ metabolomics and tar-
geted sub-compartmental measurements led to the identification of 
increased SAM-to-SAH ratio in mitochondria across models of PEMT 
deficiency, paralleling the changes observed in mitochondrial CoQ. 
Changes (up or down) to the mitochondrial SAM-to-SAH ratio were 
sufficient to alter mitochondrial CoQ. Mitochondrial CoQ concentra-
tions were unaffected by cytosolic expression of SAM synthetase (SAM1) 
whereas ectopic expression of SAM1 in mitochondria increased mito-
chondrial CoQ. These results demonstrate that it is mitochondrial rather 
than ‘cellular’ SAM and SAH per se, that are the key in modulating 
mitochondrial CoQ content, and more generally highlight the impor-
tance of measuring metabolites at subcellular resolution. 
Several lines of evidence support the conclusion that increasing 
mitochondrial CoQ via attenuated PEMT and the enhanced mitochon-
drial SAM-to-SAH ratio is beneficial in the context of insulin resistance. 
We found increasing mitochondrial CoQ via ASO-mediated PEMT 
knockdown resulted in maintenance of glucose uptake in adipocytes in 
the presence of TNFα. Increasing mitochondrial CoQ via ASO-mediated 
PEMT knockdown also maintained glucose uptake in the presence of 4- 
nitrobenzoic acid. 4-Nitrobenzoic acid is an inhibitor of COQ2, but its 
inhibitory action on CoQ synthesis and hence CoQ content was 
ameliorated by the ASO-mediated PEMT knock down. These results 
suggest that improved glucose uptake in PEMT-deficient cells is causally 
related to increased (or preserved) CoQ content. Importantly, this causal 
relationship extends to the in vivo situation: modulation of PEMT activity 
by ASO in HFD-fed mice led to maintenance of insulin sensitivity with 
improved glucose and insulin responses, and this was associated with a 
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parallel increase in mitochondrial SAM-to-SAH ratio and CoQ in the 
livers of these mice. As mitochondrial superoxide is a known driver of 
insulin resistance downstream of CoQ [11,42] and is decreased in PEMT 
deficiency, our results also uncover a previously unrecognized causal 
relationship between PEMT and mitochondrial oxidant(s). 
In addition to PEMT, our initial screen in conjunction with the yeast 
knockout collection, identified 30 previously unrecognized regulators of 
CoQ content in yeast. The genes identified in our study add to the set of 
gene mutants identified previously [45] as altering total CoQ content. 
There is limited overlap between the groups of gene mutants identified 
in each study. This is likely explained by the different growth conditions 
used, with cellular CoQ content known to be affected by the abundance 
of benzoquinone head group precursors and cellular metabolic activity. 
This highlights the complexity of the metabolic factors that govern CoQ 
synthesis and the need to consider the interaction of metabolic and ge-
netic regulators. Similarly in our study, mutants were selected for 
further analyses based on their relative CoQ content compared to other 
mutants grown on the same 96-well plate as meaningful intra-plate 
comparisons were not feasible. We cannot exclude the possibility that 
some mutants were missed in our screen, especially those that display a 
change in CoQ lower than the threshold of the screen. 
While we developed the quantitative screening method for yeast 
cells, it could be applied to most biological samples and hence aid large- 
scale studies, e.g., clinical studies requiring CoQ measurement. Most of 
the yeast genes identified have a functional mammalian homolog, 
raising the possibility for these genes to be additional conserved regu-
lators of cellular CoQ content in mammalian cells. Gene ontology (GO) 
analyses via FunSpec [46] identified 35 GO Biological Processes as 
enriched in the ‘high CoQ’ mutants, none of which have previously been 
associated with CoQ synthesis. The biological processes identified in the 
‘high CoQ’ mutant groups are in various cellular compartments in 
addition to mitochondria, e.g., endoplasmic reticulum, the Golgi 
network, and the nucleus. This suggests that several extra-mitochondrial 
processes regulate cellular CoQ content, further emphasizing the com-
plex interplay between spatially distinct pathways in the regulation of 
cellular CoQ concentrations, as we have demonstrated in the case of 
PEMT deficiency. The development of techniques such as 
MALDI-imaging to analyze CoQ distribution in vivo [47] could aid in the 
study of such issues, especially in more complex tissues. 
Our study raises several interesting questions, e.g., how mitochon-
drial concentrations of SAM and SAH are regulated, and the potential of 
our findings for translation to treat CoQ deficiency and related pathol-
ogies. What is clear from our studies is that changes in cytosolic SAM 
concentrations alone are not sufficient to increase mitochondrial SAM or 
the mitochondrial SAM-to-SAH ratio, and that the mitochondrial SAM- 
to-SAH ratio does not always reflect the whole-cell situation. While 
PEMT deficiency increases mitochondrial SAM-to-SAH ratio to benefi-
cially affect mitochondrial CoQ and cell function, ablation of PEMT as a 
therapeutic strategy poses significant challenges due to the impact of 
PEMT deficiency on hepatic lipid metabolism. Pemt–/– mice fed regular 
chow diet display no phospholipid defects [36], most likely due to the 
increased activity of the rate limiting step in the Kennedy Pathway. 
However, Pemt–/– mice fed a high-fat diet display decreased PC (~25%) 
and a decreased PC/PE ratio [25]. These mice eventually develop severe 
triglyceride accumulation, endoplasmic reticulum stress and 
non-alcoholic steatohepatitis (NASH) most likely due to a loss of mem-
brane integrity induced by the decreased PC/PE ratio [48]. Poly-
morphisms in the PEMT gene area associated with non-alcoholic fatty 
liver disease in humans [49]. Nevertheless, understanding how PEMT 
deficiency leads to increased mitochondrial SAM-to-SAH ratio may ul-
timately lead to novel strategies to increase CoQ concentrations in vivo. 
The methionine cycle is a centre piece of the methylation pathway 
and occurs in the cytosol. SAM must be transported into mitochondria 
and the SAH generated must be transported back to the cytosol for either 
conversion back to SAM or for cysteine/glutathione synthesis. It is likely 
that other factors affect how much SAM is transported into the mito-
chondria in PEMT deficiency. One potential factor could be the sub- 
cellular localization of PEMT. PEMT is localized to ER-mitochondria 
associated membranes (MAMs) [50], an interface for crosstalk be-
tween the ER and mitochondria that is integral in the appropriate 
functioning of both organelles. Therefore, it seems plausible that PEMT 
deficiency increases SAM locally in ER-MAM microdomains and that this 
facilitates SAM accessibility to CoQ biosynthetic complex and mito-
chondrial CoQ synthesis. In support this, FKBP8 is a regulator of the 
formation of the ER-mitochondria interface [51] that interacts with 
COQ9 [52], a protein essential for the stabilization of the putative CoQ 
biosynthetic complex [53]. COQ polypeptides that participate in the 
CoQ synthome are also highly enriched at ER-MAM sites [54,55]. These 
enzymes include COQ3, a SAM-dependent methyltransferase respon-
sible for both O-methylation steps in CoQ biosynthesis. We speculate 
that the increased SAM-SAH-ratio observed in mitochondria of 
PEMT-deficient cells is driven by the spatial co-enrichment of PEMT and 
CoQ biosynthetic enzymes in ER-MAM microdomains. If so, this may be 
an example of redox control at the ER-mitochondrial interface, a 
sub-cellular location also important in glucose metabolism and insulin 
signaling [56]. 
Undoubtedly further studies are necessary to fully understand the 
complex issues raised by the present study and to harness its potential to 
develop novel strategies to increase mitochondrial CoQ and overcome 
mitochondrial oxidative stress and dysfunction resulting from CoQ 
deficiency. Nevertheless, our work identifies a new network of genes 
that regulate CoQ, opening the door for further research in this area. In 
Fig. 4. Protection against IR by PEMT deficiency depends on increased mitochondrial CoQ content. (A) Mitochondrial CoQ9 content in 3T3-L1 adipocytes 
treated with control or anti-Pemt ASO, and TNFα (chronic low dose inflammation inducer) or 4-nitrobenzoic acid (4NB, an inhibitor of CoQ biosynthesis) (n = 3). 
*Significant difference between control and PEMT-ASO in the same treatment group. aSignificant difference between TNFα and 4NB treatments compared with 
vehicle in control-ASO treated cells. bSignificant difference between TNFα and 4NB treatments compared with vehicle in PEMT-ASO treated cells. #No significant 
difference between cells treated with PEMT-ASO and TNFα or 4NB compared with vehicle-treated control-ASO cells. (B) Glucose uptake in 3T3-L1 adipocytes treated 
with control or anti-Pemt ASO, and TNFα (chronic low dose inflammation inducer) or 4-nitrobenzoic acid (4NB, an inhibitor of CoQ biosynthesis) as measured by 
uptake of 3H-2-deoxyglucose (n = 5). *ns denotes significant difference or lack thereof, respectively, between control and PEMT-ASO in the same treatment group. 
aSignificant difference between TNFα and TNFα+4NB treatments compared with vehicle in control-ASO treated cells. #No significant difference between cells treated 
with PEMT-ASO and TNFα or 4NB compared with vehicle-treated control-ASO cells. (C) PEMT activity in C57BL/6J mice fed HFD treated with either control or anti- 
PEMT ASO for 10 weeks (n = 5–9). (D) Glucose tolerance test (GTT) in C57BL/6J mice fed HFD treated with either control or anti-PEMT ASO for 10 weeks (n =
5–10). For area under the curve (AUC), each data point represents the area under the curve extrapolated per animal from blood glucose concentrations determined 
over 3 h post glucose challenge. AUC was determined as outlined in the Methods. (E) Insulin tolerance test (ITT) in C57BL/6J mice fed HFD treated with either 
control or anti-PEMT ASO for 10 weeks (n = 5–10). For incremental area under the curve (iAUC), blood glucose concentrations per animal were baseline (0 min) 
corrected, and iAUC calculated from Δ blood glucose concentrations determined over 3 h post insulin challenge. (F) Mitochondrial CoQ9 concentrations in C57BL/6J 
mice fed HFD treated with either control or anti-PEMT ASO for 10 weeks (n = 5–12). (G) Mitochondrial SAM concentrations in C57BL/6J mice fed HFD treated with 
either control or anti-PEMT ASO for 10 weeks (n = 5–12). (H), Mitochondrial SAM/SAH ratio in C57BL/6J mice fed HFD treated with either control or anti-PEMT 
ASO for 10 weeks (n = 5–12). (I) Schematic summary of results and proposed mechanism. PEMT deficiency increases cytosolic SAM resulting in increased mito-
chondrial SAM and SAM/SAH. Increased mitochondrial SAM increases CoQ biosynthesis by donating methyl groups to the benzoquinone head group of CoQ formed 
from 4-hydroxybenzoic acid (4HB). Increased mitochondrial CoQ results in decreased mitochondrial superoxide, an upstream driver of insulin resistance. Data and 
error bars depict mean ± s.e.m. *P ≤ 0.05 as determined by Mann-Whitney (C–H) or Kruskal-Wallis test (A, B). 
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addition, the identification of the intersection of phospholipid meta-
bolism, mitochondrial one-carbon metabolism, and CoQ synthesis in 
PEMT deficiency, and how these interact in the setting of insulin resis-
tance represents an exciting advance in our understanding of one-carbon 
metabolism, lipid biology and mitochondrial function. 
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[44] U. Forsman, M. Sjöberg, M. Turunen, P.J. Sindelar, 4-Nitrobenzoate inhibits 
coenzyme Q biosynthesis in mammalian cell cultures, Nat. Chem. Biol. 6 (2010) 
515–517. 
[45] J.A. Stefely, et al., Mitochondrial protein functions elucidated by multi-omic mass 
spectrometry profiling, Nat. Biotechnol. 34 (2016) 1191–1197. 
A. Ayer et al.                                                                                                                                                                                                                                    
Redox Biology 46 (2021) 102127
14
[46] M.D. Robinson, J. Grigull, N. Mohammad, T.R. Hughes, FunSpec: a web-based 
cluster interpreter for yeast, BMC Bioinf. 3 (2002) 35. 
[47] Y. Tatsuta, et al., Imaging mass spectrometry analysis of ubiquinol localization in 
the mouse brain following short-term administration, Sci. Rep. 7 (2017) 12990. 
[48] J.N. van der Veen, et al., The critical role of phosphatidylcholine and 
phosphatidylethanolamine metabolism in health and disease, Biochim. Biophys. 
Acta Biomembr. 1859 (2017) 1558–1572. 
[49] J. Song, et al., Polymorphism of the PEMT gene and susceptibility to nonalcoholic 
fatty liver disease (NAFLD), FASEB J. 19 (2005) 1266–1271. 
[50] J.E. Vance, Phospholipid synthesis in a membrane fraction associated with 
mitochondria, J. Biol. Chem. 265 (1990) 7248–7256. 
[51] C. Kwak, et al., Contact-ID, a tool for profiling organelle contact sites, reveals 
regulatory proteins of mitochondrial-associated membrane formation, Proc. Natl. 
Acad. Sci. U.S.A. 117 (2020) 12109–12120. 
[52] B.J. Floyd, et al., Mitochondrial protein interaction mapping identifies regulators 
of respiratory chain function, Mol. Cell. 63 (2016) 621–632. 
[53] D.C. Lohman, et al., Mitochondrial COQ9 is a lipid-binding protein that associates 
with COQ7 to enable coenzyme Q biosynthesis, Proc. Natl. Acad. Sci. U.S.A. 111 
(2014) E4697–E4705. 
[54] M. Eisenberg-Bord, et al., The endoplasmic reticulum-mitochondria encounter 
structure complex coordinates coenzyme Q biosynthesis, Contact 2 (2019), 
2515256418825409. 
[55] K. Subramanian, et al., Coenzyme Q biosynthetic proteins assemble in a substrate- 
dependent manner into domains at ER-mitochondria contacts, J. Cell Biol. 218 
(2019) 1353–1369. 
[56] E. Tubbs, et al., Disruption of mitochondria-associated endoplasmic reticulum 
membrane (MAM) integrity contributes to muscle insulin resistance in mice and 
humans, Diabetes 67 (2018) 636–650. 
A. Ayer et al.                                                                                                                                                                                                                                    
